![Molecules, microbes and multiomics artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts123/v4/2a/46/b6/2a46b600-b6b5-c4f1-d8d4-effc21fead7a/mza_8592612661371652922.png/100x100bb.jpg)
A look ahead for the microbiome industry
Molecules, microbes and multiomics
English - March 27, 2019 12:48 - 16 minutes - 15 MB - ★★★★★ - 3 ratingsLife Sciences Science Technology rna dna genomics microbiome multiomics Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: The microbiome challenges CoreBiome was built to solve
Next Episode: Urine as a liquid biopsy for cancer detection
We recently introduced listeners of Molecules, microbes and multiomics to our sister company, CoreBiome, a privately-held, Minnesota-based microbiome analysis company that accelerates discovery for customers in the pharmaceutical, agricultural, environmental and research communities. We are continuing this story via an interview with CoreBiome co-founder, Dr. Dan Knights.
In this new podcast, Dr. Knights speaks to us about why the microbiome is so different from the human genome, what answers microbiome research can provide for wellness and disease that we can’t find elsewhere, and what advice he would give an epidemiologist who is looking to add a microbiome component to their project.